


RealRate

PHARMACEUTICAL 2019

LUMOS PHARMA INC. Rank 48 of 363









RealRate

PHARMACEUTICAL 2019

LUMOS PHARMA INC. Rank 48 of 363



The relative strengths and weaknesses of LUMOS PHARMA INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LUMOS PHARMA INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 52% points. The greatest weakness of LUMOS PHARMA INC. is the variable Research and Development, reducing the Economic Capital Ratio by 9.2% points.

The company's Economic Capital Ratio, given in the ranking table, is 234%, being 197% points above the market average of 37%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 127,072 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 8,847 |
| Liabilities, Non-Current | 6,949 |
| Other Assets | 49,940 |
| Other Compr. Net Income | 0 |
| Other Expenses | -6,968 |
| Other Liabilities | 0 |
| Other Net Income | 1,875 |
| Other Revenues | 12,500 |
| Property and Equipment | 3,727 |
| Research and Development | 45,694 |
| Selling, General and Administrative Expense | 29,218 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 180,739 |
| Liabilities | 15,796 |
| Expenses | 67,944 |
| Revenues | 12,500 |
| Stockholders Equity | 164,943 |
| Net Income | -53,569 |
| Comprehensive Net Income | -53,569 |
| Economic Capital Ratio | 234% |

